-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
-
Summary
-
Revance Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2012 to 2023.
- Revance Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $6.03M, a 55.3% decline year-over-year.
- Revance Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $39.5M, a 25.6% decline year-over-year.
- Revance Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $49.2M, a 6.02% decline from 2022.
- Revance Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $52.3M, a 20.5% increase from 2021.
- Revance Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $43.4M, a 19.2% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)